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ABSTRACT
A prospective study was performed of patients diagnosed with colorectal cancer 
(CRC), distinguishing between colonic and rectal location, to determine the factors 
that may provoke a delay in the first treatment (DFT) provided.
2749 patients diagnosed with CRC were studied. The study population was 
recruited between June 2010 and December 2012. DFT is defined as time elapsed 
between diagnosis and first treatment exceeding 30 days.
Excessive treatment delay was recorded in 65.5% of the cases, and was more 
prevalent among rectal cancer patients. Independent predictor variables of DFT 
in colon cancer patients were a low level of education, small tumour, ex-smoker, 
asymptomatic at diagnosis and following the application of screening. Among rectal 
cancer patients, the corresponding factors were primary school education and being 
asymptomatic.
We conclude that treatment delay in CRC patients is affected not only by 
clinicopathological factors, but also by sociocultural ones. Greater attention should 
be paid by the healthcare provider to social groups with less formal education, in 
order to optimise treatment attention.
INTRODUCTION
Colorectal cancer (CRC) is a major public health 
problem, with major impact on morbidity and mortality. It 
is the second most prevalent malignancy worldwide, and is 
also second in incidence and mortality in most developed 
countries. In Europe, five-year survival rates are 44-64%, 
and in Spain the EUROCARE-4 project calculated a 
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survival rate of 61.5% [1]. As a result of population aging, 
together with diagnostic and therapeutic advances, the 
number of cancer patients has increased significantly, and 
this situation is placing great pressure on the cancer care 
system, reflecting the growing importance of this group of 
diseases as a public health problem.
Early diagnosis of cancer and hence early treatment 
is a fundamental objective in cancer care procedures. 
Although delays attributable to the health system 
constitute a small proportion of the biological life of a 
tumour, noticeable hospital delay (from first hospital visit 
to diagnosis or from diagnosis to treatment) may provoke 
stress and decrease the patient’s quality of life. In fact, 
delays in initiating treatment are the leading cause of 
malpractice complaints [2].
While some studies indicate that treatment delay 
negatively affects the prognosis of patients with cancer, 
particularly CRC, others have found no such association 
[3, 4]. Moreover, it has been reported that delay is often 
attributable to tumour factors such as clinical stage and 
location, and not only to the health system, such as 
hospital admission procedures. The impact of treatment 
delay on survival, and the significance of the diverse 
factors involved, have yet to be determined [5]. Waiting 
time is a complex variable, which can reflect the patient’s 
own behaviour, the clinical course, the functioning of the 
health system and tumour biology [6].
Taking into account the dearth of prospective studies 
designed to analyse treatment delay, with large cohorts of 
patients and distinguishing between colonic and rectal 
tumours, in this study we evaluate the degree to which 
treatment delay is influenced by the sociodemographic 
conditions of patients and by the clinical and pathological 
characteristics of the tumour.
RESULTS
Descriptive analysis
During the recruitment period, the 22 participating 
centres recruited 2,749 patients who met the criteria 
for inclusion. Of these, 330 (12%) were later excluded 
from the study because it was not possible to determine 
the treatment delay. Thus, the final patient sample was 
composed of 2,419 records. The sociodemographic and 
clinicopathological characteristics of the study population 
are shown in Table 1.
Treatment delays and types of treatment
For all tumours, the most common initial treatment 
was surgery (81.4%), followed by chemotherapy 
(13%) (p<0.001). For rectal tumours alone, surgery and 
chemotherapy were also the most common treatment 
options (40.5% and 39.5%, respectively).
A histogram showing the distribution of treatment 
delay is shown in Figure 1. A delay to first treatment 
exceeding 30 days was recorded in 65.5% of cases [95% 
CI: 63.6-67.4], and this value was higher (p<0.001) for 
rectal tumours (74.4%) than for colon tumours (62.2%) 
(Table 2). Stratifying according to the first mode of 
treatment administered and by tumour location, there 
was a higher frequency of delay for surgical treatment for 
rectal tumours than for colon tumours (79.2% vs. 62.2%) 
(p<0.001). No significant differences were observed for 
the other treatment strategies.
Relation between treatment delay and 
the patients’ sociodemographic and 
clinicopathological characteristics
In our analysis of the relation between the presence 
of DFT and each of the sociodemographic variables, 
those that were significantly associated with greater 
DFT in patients with cancer of the colon were male sex, 
low level of education or no formal education, BMI 
(28±5.1), ex-smoker and asymptomatic at diagnosis. The 
most relevant tumour characteristics were small local 
extension and the absence of nodes, of metastasis and 
of perineural invasion. Treatment delays in patients with 
tumours presenting normal values for carcinoembryonic 
antigen and for cancer antigen 19-9 were greater than 
among patients presenting abnormal values for these 
parameters. Finally, the treatment delay in patients who 
had received prior screening was greater than among 
those who had not had this test (Table 3). For rectal 
tumours, the variables that were significantly related to 
a higher level of DFT were primary studies or no formal 
education, being asymptomatic and having had prior 
screening (Table 4).
After adjusting for variables found to be statistically 
significant in the crude analysis, the multivariate analysis 
revealed the following to be independent protective factors 
against increased DFT: having university studies, for colon 
cancer [OR = 0.69; 95% CI 0.52-0.91] and for rectal cancer 
[OR = 0.56; 95% CI 0.34-0.91]; later tumour stage, for 
colon tumours, T3-T4, [OR = 0.51; 95% CI 0.37-0.69]; 
and for rectal tumours, the presence of severe [OR = 0.31; 
95% CI 0.09-1.07] or moderate symptoms [OR = 0.67; 
95% CI 0.16-2.74], compared with asymptomatic patients. 
However, DFT was greater in the patients with colon cancer 
who were ex-smokers [OR = 1.40; 95% CI 1.09-1.80] and 
in those who had had prior screening [OR = 1.79; 95% CI: 
1.32-2.43] (Tables 3 and 4).
DISCUSSION
Our study highlights the existence of delayed 
implementation of the first treatment among 65.5% of the 
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Table 1: Sociodemographic and clinical characteristics for all cases and segmented by type of tumour
Total Colon Rectal p
n % n % n %
Sex
  Male 1539 63.6 1092 62.2 447 67.3 0.023
  Female 880 36.4 663 37.8 217 32.7
Age
  Mean - SD 68.3 ±10.9 68.8 ±10.8 66.9 ±11.0 <0.001
Marital status1
  Single 150 7.6 100 6.9 50 9.1 0.048
  Married-Cohabiting 1434 72.2 1028 71.4 406 74.2
  Separated-Divorced 100 5.0 76 5.3 24 4.4
  Widowed 302 15.2 235 16.3 67 12.2
Education profile2
  No education-Primary 
education 1531 77.2 1114 77.1 417 77.2 1.000
  Secondary-University 453 22.8 330 22.9 123 22.8
Currently in work3
  No 1493 76.3 1072 75.3 421 78.7 0.135
  Yes 465 23.7 351 24.7 114 21.3
BMI4
  Mean - SD 27.7 ±4.8 28.0 ±4.9 27.1 ±4.5 <0.001
Smoking habit5
  Never 1109 47.8 831 49.6 278 43.3 0.008
  Current smoker 302 13.0 201 12.0 101 15.7
  Ex-smoker 908 39.2 645 38.5 263 41.0
Family history of neoplasias6
  No 1339 61.3 990 63.1 349 56.7 0.007
  Yes 846 38.7 580 36.9 266 43.3
Family history of CRC7
  No 1295 86.2 934 86.3 361 85.7 0.837
  Yes 208 13.8 148 13.7 60 14.3
Specific signs and symptoms8
  Asymptomatic 204 8.8 160 9.6 44 6.9 <0.001
  Moderate signs and symptoms 381 16.5 300 18.0 81 12.6
  Severe signs and symptoms 1724 74.7 1207 72.4 517 80.5
Type of tumour
  Colon 1755 72.6
  Recto 664 27.4
(Continued )
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population diagnosed with CRC. This finding lies within the 
40-70% range of treatment delay previously reported [7].
Studies have been conducted to evaluate the 
prognostic influence of diagnostic and treatment delays 
on different types of cancer, and to determine the 
significant factors in this process. However, conflicting 
results have been obtained, due in part to differences 
in the characteristics of the populations analysed; 
furthermore, in most cases, the cohorts have been 
examined retrospectively and there have been differences 
in the time intervals studied [8]. This is a controversial 
issue, and it remains to be clarified. Unlike these earlier 
Total Colon Rectal p
n % n % n %
Size of tumour9
  Locally small (T0-T1-T2) 681 28.8 376 21.9 305 47.0 <0.001
  Locally large (T3-T4) 1686 71.2 1342 78.1 344 53.0
Lymph nodes10
  Absent 1464 62.7 1028 60.0 436 70.1 <0.001
  Present 871 37.3 685 40.0 186 29.9
Histological diagnosis11
  Adenocarcinoma 2152 89.6 1555 89.0 597 91.3 0.121
  Mucinous carcinoma or other 
types 249 10.4 192 11.0 57 8.7
Metastasis12
  Absent 2057 91.9 1483 91.2 574 93.8 0.056
  Present 181 8.1 143 8.8 38 6.2
Differentiation13
  Low grade 1790 86.9 1333 86.4 457 88.2 0.336
  High grade 270 13.1 209 13.6 61 11.8
Vascular invasion14
  Absent 1764 86.4 1259 84.4 505 92.0 <0.001
  Present 277 13.6 233 15.6 44 8.0
Perineural invasion15
  Absent 1627 81.4 1165 80.1 462 84.8 0.019
  Present 373 18.7 290 19.9 83 15.2
Carcinoembryonic antigen (CEA)16
  Normal (0-5) 1328 68.7 917 67.5 411 71.6 0.083
  Abnormal (>5) 605 31.3 442 32.5 163 28.4
Cancer antigen 19-917
  Normal (1-37) 944 85.4 620 84.1 324 88.0 0.099
  Abnormal (>37) 161 14.6 117 15.9 44 12.0
Prior screening18
  No 1868 80.8 1330 79.1 538 85.4 0.001
  Yes 443 19.2 351 20.9 92 14.6
Losses: 1=433; 2=435; 3=461; 4=552; 5=100; 6=234; 7=916; 8=110.
Losses: 9=52; 10=84; 11=18; 12=181; 13=359; 14=378; 15=419; 16=486; 17=1314; 18=108
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studies, our own research is based on a large number of 
patients recruited prospectively. We define excessive delay 
between diagnosis and treatment as a period exceeding 
30 days, following previous recommendations and reports 
in this respect [9, 10, 11, 12, 13]
Unlike other studies on diagnostic and treatment 
delays in patients with CRC, our study population is 
distributed according to the location of the tumour (colon 
or rectal), in view of the well-known differences in the 
pathogenesis of each. We found DFT to be significantly 
greater for rectal tumours, as was also reported in the 
case of delay attributable to the patient [14]. Analysis of 
the delay according to the type of first treatment applied 
showed that this difference persisted when the first 
treatment was surgery, but not when it was chemotherapy 
or radiotherapy. This association is consistent with the 
findings of other studies, which have related the delay 
in surgical treatment for advanced stage (according to 
the Dukes system) rectal tumours, but not for tumours of 
the colon [15], probably because in localised and locally-
advanced rectal tumours, and unlike for colon cancer, other 
diagnostic tests are required prior to treatment, such as 
pelvic magnetic resonance imaging and rectal endoscopic 
ultrasound examination [16]. Another difference between 
the two types of cancer was the relationship between DFT 
and the digestive symptoms diagnosed; a shorter DFT was 
only observed in patients with rectal cancer and moderate 
to severe symptoms, compared with mildly symptomatic 
or asymptomatic patients. Possibly the more pronounced 
and alarming symptoms resulting from rectal tumours, 
i.e. bleeding and pain, compared to the less specific and 
subacute ones provoked by colon tumours, lead patients 
with rectal cancer to seek a medical consultation at an 
earlier stage, thus expediting the diagnostic-therapeutic 
circuit. The physician prescribing the treatment will 
probably give preference to symptomatic patients, who 
are at increased risk of presenting complications from 
the tumour and therefore have a worse prognosis. It 
should also be taken into account that some patients with 
advanced tumours do not state the actual date of onset of 
Figure 1: Frequency histogram of delay (in days) to first treatment for patients with CRC.
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Table 2: Type of first treatment and delays
Total Colon Rectal p
n % n % n %
First line of treatment
  Surgery 1968 81.4 1699 96.8 269 40.5 <0.001
  Chemotherapy1 314 13.0 52 3.0 262 39.5
  Radiotherapy 137 5.7 4 0.2 133 20.0
Delay in first treatment
  ≤30 days 834 34.5 664 37.8 170 25.6 <0.001
  >30 days 1585 65.5 1091 62.2 494 74.4
Delay before surgery
  ≤30 days 699 35.5 643 37.8 56 20.8 <0.001
  >30 days 1269 64.5 1056 62.2 213 79.2
Delay before chemotherapy
  ≤30 days 96 30.6 20 38.5 76 29.0 0.235
  >30 days 218 69.4 32 61.5 186 71.0
Delay before radiotherapy
  ≤30 days 39 28.5 1 25.0 38 28.6 1.000
  >30 days 98 71.5 3 75.0 95 71.4
1 With or without radiotherapy
Table 3: Bivariate and multivariate analysis with DFT in patients with colon cancer
≤30 days >30 days Crude analysis Adjusted analysis*
n % n % p OR 95% CI p OR 95% CI
Sex
  Male 393 36.0 699 64.0 0.041 1.00
  Female 271 40.9 392 59.1 0.81 [0.67-0.99]
Age
  Mean - SD 68.8 ±11.3 68.8 ±10.4 0.915 1.00 [0.99-1.01]
Marital status
  Single 38 38.0 62 62.0 0.182 1.00
  Married-Cohabiting 374 36.4 654 63.6 1.07 [0.70-1.64]
  Separated-Divorced 21 27.6 55 72.4 1.60 [0.84-3.06]
  Widowed 97 41.3 138 58.7 0.87 [0.54-1.41]
Education profile
  No education-
Primary education
388 34.8 726 65.2 0.001 1.00 0.008 1.00
  Secondary-
University 148 44.8 182 55.2 0.66 [0.51-0.84] 0.69[0.52-0.91]
(Continued )
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≤30 days >30 days Crude analysis Adjusted analysis*
n % n % p OR 95% CI p OR 95% CI
Currently in work
  No 396 36.9 676 63.1 0.482 1.00
  Yes 137 39.0 214 61.0 0.91 [0.71-1.17]
BMI
  Mean - SD 27.2 ±4.4 28.4 ±5.1 <0.001 1.06 [1.03-1.08]
Smoking habit
  Never 332 40.0 499 60.0 0.017 1.00 0.028 1.00
  Current smoker 83 41.3 118 58.7 0.95 [0.69-1.29] 1.08[0.74-1.57]
  Ex-smoker 215 33.3 430 66.7 1.33 [1.07-1.65] 1.40[1.09-1.80]
Family history of neoplasias
  No 374 37.8 616 62.2 0.952 1.00
  Yes 220 37.9 360 62.1 0.99[0.80-1.23]
Family history of CRC
  No 323 34.6 611 65.4 0.212 1.00
  Yes 59 39.9 89 60.1 0.80[0.56-1.14]
Specific signs and symptoms
  Asymptomatic 40 25.0 120 75.0 <0.001 1.00
  Moderate signs and 
symptoms 132 44.0 168 56.0 0.42[0.28-0.65]
  Severe signs and 
symptoms 466 38.6 741 61.4 0.53[0.36-0.77]
Size of tumour
  Locally small (T0-
T1-T2)
96 25.5 280 74.5 <0.001 1.00 <0.001 1.00
  Locally large (T3-T4) 555 41.4 787 58.6 0.49[0.37-0.63] 0.51[0.37-0.69]
Lymph nodes
  Absent 365 35.5 663 64.5 0.015 1.00
  Present 283 41.3 402 58.7 0.78[0.64-0.95]
Histological diagnosis
  Adenocarcinoma 585 37.6 970 62.4 0.597 1.00
  Mucinous 
carcinoma 76 39.6 116 60.4 0.92[0.68-1.25]
Metastasis
  Absent 523 35.3 960 64.7 0.037 1.00
  Present 63 44.1 80 55.9 0.69[0.49-0.98]
Differentiation
  Low grade 490 36.8 843 63.2 0.223 1.00
  High grade 86 41.1 123 58.9 0.83[0.62-1.12]
(Continued )
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Table 4: Bivariate and multivariate analysis with DFT in patients with rectal cancer
≤30 days >30 days Crude analysis Adjusted analysis*
n % p OR
95% CI
p OR
95% CI
p OR
95% CI
Sex
  Male 109 24.4 338 75.6 0.303 1.00
  Female 61 28.1 156 71.9 0.82[0.57-1.19]
Age
  Mean - SD 65.9 ±11.2 67.2 ±11.0 0.168 1.01[0.99-1.03]
Marital status
  Single 9 18.0 41 82.0 0.145 1.00
  Married-Cohabiting 111 27.3 295 72.7 0.58[0.27-1.24]
  Separated-Divorced 2 8.3 22 91.7 2.41[0.48-12.17]
  Widowed 18 26.9 49 73.1 0.60[0.24-1.47]
Education profile
  No education-Primary 
education 97 23.3 320 76.7 0.025 1.00 0.020 1.00
≤30 days >30 days Crude analysis Adjusted analysis*
n % n % p OR 95% CI p OR 95% CI
Vascular invasion
  Absent 475 37.7 784 62.3 0.212 1.00
  Present 98 42.1 135 57.9 0.83[0.63-1.11]
Perineural invasion
  Absent 426 36.6 739 63.4 0.001 1.00
  Present 137 47.2 153 52.8 0.64[0.50-0.83]
Carcinoembryonic antigen (CEA)
  Normal (0-5) 324 35.3 593 64.7 0.010 1.00
  Abnormal (>5) 188 42.5 254 57.5 0.74[0.58-0.93]
Cancer antigen 19-9
  Normal (1-37) 219 35.3 401 64.7 0.011 1.00
  Abnormal (>37) 56 47.9 61 52.1 0.59[0.40-0.89]
Prior screening
  No 547 41.1 783 58.9 <0.001 1.00 <0.001 1.00
  Yes 89 25.4 262 74.6 2.06[1.59-2.68] 1.79[1.32-2.43]
First line of treatment
  Surgery 643 37.8 1056 62.2 0.869 1.00
  Chemotherapy 20 38.5 32 61.5 0.97[0.55-1.72]
  Radiotherapy 1 25.0 3 75.0 1.83[0.19-17.6]
* In multivariate logistic regression with a sample of 1,291 patients
(Continued )
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≤30 days >30 days Crude analysis Adjusted analysis*
n % p OR
95% CI
p OR
95% CI
p OR
95% CI
  Secondary-University 41 33.3 82 66.7 0.61[0.39-0.94] 0.56[0.34-0.91]
Currently in work
  No 107 25.4 314 74.6 0.845 1.00
  Yes 30 26.3 84 73.7 0.95[0.60-1.53]
BMI
  Mean - SD 26.9 ±4.1 27.1 ±4.7 0.699 1.01[0.96-1.05]
Smoking habit
  Never 71 25.5 207 74.5 0.989 1.00
  Current smoker 26 25.7 75 74.3 0.99[0.59-1.67]
  Ex-smoker 66 25.1 197 74.9 1.02[0.69-1.51]
Family history of neoplasias
  No 88 25.2 261 74.8 0.757 1.00
  Yes 70 26.3 196 73.7 0.94[0.66-1.36]
Family history of CRC
  No 91 25.2 270 74.8 0.386 1.00
  Yes 12 20.0 48 80.0 1.35[0.87-2.65]
Specific signs and symptoms
  Asymptomatic 4 9.1 40 90.9 0.009 1.00 0.031 1.00
  Moderate signs and 
symptoms 15 18.5 66 81.5 0.44[0.14-1.42] 0.67[0.16-2.74]
  Severe signs and 
symptoms 146 28.2 371 71.8 0.25(0.09-0.72) 0.31[0.09-1.07]
Size of tumour
  Locally small (T0-
T1-T2)
78 25.6 227 74.4 0.998 1.00
  Locally large (T3-T4) 88 25.6 256 74.4 1.00[0.70-1.42]
Lymph nodes
  Absent 116 26.6 320 73.4 0.292 1.00
  Present 42 22.6 144 77.4 1.42[0.83-1.86]
Histological diagnosis
  Adenocarcinoma 152 25.5 445 74.5 0.660 1.00
  Mucinous carcinoma 13 22.8 44 77.2 1.16[0.61-2.20]
Metastasis
  Absent 138 24.0 436 76.0 0.751 1.00
  Present 10 26.3 28 73.7 0.89[0.42-1.87]
(Continued )
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their symptoms, or minimise it, due to a feeling of guilt at 
not having consulted the doctor sooner, and this too can 
exacerbate the DFT [17–19].
Studies of CRC have evaluated the relationship 
between tumour stage and diagnostic and therapeutic 
delays, and have found no association between these 
parameters [20]. Although some studies have shown 
that the DFT is shorter for patients presenting advanced 
stages of the disease [21], others have concluded the 
opposite [22]. Nevertheless, these conclusions cannot be 
generalised for tumours of the colon and rectum as if they 
were a single entity; on the contrary, they must be analysed 
independently, in view of the different natural history 
presented in each case [23, 24]. Thus, some retrospective 
studies have shown that advanced rectal tumours present 
an increased risk of DFT, in comparison with the initial 
stages, while no such differences were found for cancers 
of the colon [15]. On the other hand, in our own study, 
tumour stages T1-T2 experienced greater DFT than more 
advanced stages, but only in tumours of the colon. This 
difference might arise from the lower priority assigned 
to treatment for early-stage cancers, when symptoms 
are usually less apparent and hence delay the start of 
the therapeutic process. In a study of breast cancer, our 
group evaluated the different periods of delay, noting that 
higher tumour stages were associated with a shorter DFT, 
which was associated with a lower disease-free survival 
time. This outcome is probably produced by the priority 
granted by doctors to patients whose symptoms are more 
severe [6], which contradicts the traditional view that 
greater delay is associated with decreased survival time. 
This inverse correlation between treatment delay and 
survival has been described previously in studies of the 
endometrium and the lung [25, 26].
In our analysis of clinicopathological characteristics 
with known prognostic value and associated with increased 
≤30 days >30 days Crude analysis Adjusted analysis*
n % p OR
95% CI
p OR
95% CI
p OR
95% CI
Differentiation
  Low grade 106 23.2 351 76.8 0.175 1.00
  High grade 19 31.1 42 68.9 0.67[0.37-1.20]
Vascular invasion
  Absent 127 25.1 378 74.9 0.490 1.00
  Present 9 20.5 35 79.5 1.31[0.61-2.79]
Perineural invasion
  Absent 112 24.2 350 75.8 0.042 1.00 0.051 1.00
  Present 29 34.9 54 65.1 0.60[0.36-0.98] 0.57[0.32-1.00]
Carcinoembryonic antigen (CEA)
  Normal (0-5) 105 25.5 306 74.5 0.722 1.00
  Abnormal (>5) 44 27.0 119 73.0 0.93[0.61-1.40]
Cancer antigen 19-9
  Normal [1–37] 70 21.6 254 78.4 0.133 1.00
  Abnormal [>37] 14 31.8 30 68.2 0.59[0.30-1.17]
Prior screening
  No 148 27.5 390 72.5 0.025 1.00
  Yes 15 16.3 77 83.7 1.95[1.09-3.49]
First line of treatment
  Surgery 56 20.8 213 79.2 0.067 1.00
  Chemotherapy 76 29.0 186 71.0 0.64[0.43-0.96]
  Radiotherapy 38 28.6 95 71.4 0.66[0.41-1.06]
* In multivariate logistic regression with a sample of 433 patients
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tumour aggressiveness, the degree of histological 
differentiation and of lymphovascular invasion presented 
no relation to DFT. However, they were found to be 
related to distant metastases, lymph node involvement, 
perineural invasion and elevated tumour markers, all of 
which decrease the risk of severe DFT. However, when a 
multivariate analysis was performed, and other variables 
were taken into account, these differences did not persist, 
probably because the variables in question are more 
dependent on the biological behaviour of the tumour 
and on its intrinsic aggressiveness than on the period of 
treatment delay, as suggested by Symonds in a study of 
cervical cancer [27]. In other tumours, such as breast 
cancer, a significant association has also been described 
between the presence of more aggressive features and a 
shorter delay in initiating treatment; such features may 
include the non expression of hormone receptors, or 
non response to hormonal treatments in tumours that do 
express hormone receptors. These findings suggest that 
treatment may be expedited when the physician is aware 
of the extent of the tumour [6].
Among the sociocultural factors analysed, the 
lack of formal education or only having had primary 
education significantly increases the risk of DFT, for both 
rectal and colon tumours. Interestingly, this association, 
which has not received much previous research attention, 
influences DFT independently of other factors. One 
explanation for this might be that these patients do not 
understand the instructions received during the diagnosis-
therapy process, and may also fail to keep the medical 
appointments necessary for a definitive tumour treatment 
to be undertaken. This population group, with a low 
cultural level, might also delay the start of treatment for 
fear of future treatments and distrust of the benefit derived 
from them. This possibility was raised in a recent study 
in which DFT was associated with a lack of knowledge 
of symptoms suggestive of cancer, and with the patient’s 
unwillingness to visit the doctor, among other factors 
[28]. For these reasons, we believe that among certain 
population groups, with unhealthy living habits and a low 
educational profile, the risk of severe DFT is greater. In 
this respect, a retrospective study was conducted to obtain 
an ecological estimation of the socioeconomic status of 
patients with cancer (European Deprivation Index). No 
such relationship with DFT or with diagnostic delay was 
found, although it should be noted that this study included 
different types of cancer, with only 116 CRC [29].
Retrospective studies have evaluated social factors 
that might influence treatment delay, noting that black 
and/or elderly patients with rectal cancer were subject to 
greatest delay in initiating adjuvant chemotherapy [30]. 
In another study, of bowel cancer [31], elderly and/or 
unmarried patients were found to be most subject to this 
delay. Other studies evaluating prehospital delay have also 
found that lower socioeconomic level and lower education 
level are relevant factors. [14, 32].
Another feature of our population which the 
univariate analysis showed to be associated with increased 
treatment delay was a high BMI (>28) in patients with 
colon cancer. This relation would be explained, in part, 
by the complication of abdominal examination in the 
presence of a large pannus. One of the main causes of 
obesity in the West is an unhealthy living habit in terms 
of diet and exercise; this, too, is associated with a low 
socio-cultural level, which as mentioned previously is an 
independent predictor of treatment delay. The remaining 
demographic variables analysed–sex, age at diagnosis, 
family history of cancer, marital status and occupation–
bore no significant relation with DFT.
The relationship between treatment delay and ex-
smokers is a complex one. Elderly ex-smokers probably 
have more limitations of the respiratory function and 
require a larger number of tests before surgery. On the 
other hand, a patient who gives up smoking will probably 
believe him/herself at less risk of serious disease than a 
continuing smoker, and this factor, too, may influence 
communication with the doctor after diagnosis. In this 
respect, Mosher et al., in a study of patients diagnosed 
with lung cancer, reported that most ex-smokers rejected 
psychological therapy [33].
Our results show that a prior positive screening, 
in which faecal occult blood is detected, is associated 
with a greater risk of treatment delay; this relation has 
not been reported in previous studies. A priori, it seems 
illogical that a patient who has received CRC screening 
before any treatment is undertaken should suffer a delay 
for this reason. However, probably due to the person’s 
asymptomatic state at the time of the consultation, no 
preference is expressed (unlike the case of a patient with 
manifest symptoms and at increased risk of complications 
from the tumour, requiring prompt treatment). 
Nevertheless, we considered the possible existence of 
confounding and of interaction with the other variables, 
and always obtained the same relationship between prior 
screening and subsequent treatment delay. Neither were 
there any interaction terms to be retained in the final 
model (data not shown).
Although it has been shown that delayed diagnosis 
and treatment does not appear to increase the risk of 
death in patients with symptomatic CRC, among the 
asymptomatic population early diagnosis and treatment 
may play a role in reducing morbidity and mortality [34]. 
The results presented should be considered with caution, 
and are subject to further analysis to determine whether, 
in the screened population, the greater delay observed 
impacts on survival.
The delay before cancer treatment is started is an 
important factor to be evaluated. This delay, which is 
a criterion of health care quality, should be prevented 
and reduced as far as possible in order to avoid the 
psychologically negative impact it may cause to patients. 
Numerous studies have shown that treatment delay is 
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associated with certain clinical factors in CRC, but the 
present study is the first to establish that DFT depends 
not only on clinicopathological characteristics of the 
tumour, or on deficiencies of the healthcare system, but 
also on sociocultural characteristics of the population. 
We conclude, therefore, that more attention should be 
paid to health education regarding the initial symptoms 
related to this disease, especially among less educated 
social groups. The physician responsible for the patient’s 
treatment, too, must be aware that these patients require 
special attention.
Finally, more multicentre studies should be 
conducted, in other countries and where different 
healthcare plans are used, in order to generalise the 
findings of our study. Another valuable area for future 
research would be to determine whether treatment delay 
also impacts on survival, as this association has not been 
clarified in recent reviews of the question [6, 35].
MATERIALS AND METHODS
Study design
This prospective, multicentre observational study 
was conducted in coordination with 22 public-sector 
hospitals in six regions of Spain (Andalusia, Canary 
Islands, Catalonia, Madrid, Valencia and the Basque 
Country) [36].
The patients were recruited prospectively and 
consecutively at each of the participating hospitals 
between June 2010 and December 2012. The study 
population included patients diagnosed with new colon or 
rectum cancer, stage I-IV and surgically treated, whether 
urgently or scheduled. All patients were included, whether 
or not they had previously received treatment, and a follow 
up study of five years was scheduled. Data were compiled 
directly from patients and also from their medical history.
Study definitions
Excessive treatment delay was defined as an interval 
exceeding 30 days from pathological diagnosis to first 
treatment, in accordance with national guidelines and 
previous reports [10–13, 15]. First treatment was taken 
to be surgery, chemotherapy, radiotherapy, biological 
therapy or best supportive care. Date of diagnosis was 
the date when histological confirmation of the process 
was obtained, unless this coincided with the date of the 
intervention. In this case, we used as first date of diagnosis 
the suspected diagnosis [36].
The anatomical location of the tumour and the 
histology findings were coded in accordance with the 
International Classification for Oncology (ICD-O). Staging 
classification was based on the TNM recommendations of 
the International Union Against Cancer, 7th edition.
The following inclusion criteria were applied:
• Patients diagnosed with cancer of the colon (up to 
15 cm above the anal margin) or of the rectum (between the 
anal margin and 15 cm above it), to which curative and/or 
palliative surgical treatment was applied for the first time.
• Signed informed consent provided.
The exclusion criteria were:
• Patients diagnosed with cancer of the colon or 
rectum in situ.
• Unresectable tumours.
• Mental or physical disorders that prevented the 
patient from answering the questionnaires.
• Terminal patients
The project was evaluated by the corresponding 
Research Committees and Clinical Research Ethics 
Committees at the hospitals. Informed consent was 
requested of the patients before surgery. Current legislative 
requirements regarding personal data (any information 
concerning individuals who were identified or identifiable) 
were followed at all times. All personal data were 
processed in such a way that the information obtained 
could not be associated with identified or identifiable 
persons (Protection of Personal Data Act, 15/1999, 13-12).
Study variables
Data were compiled regarding the patients’ medical 
history: Sex, age, body mass index, prior screening, date 
of first contact with the hospital, first diagnosis, start of 
treatment, and the various types of first treatment considered 
(surgery, chemotherapy, radiotherapy, biological therapy or 
best supportive care). The date of diagnosis was taken as 
the date when the first histopathological report identifying 
the presence of cancer, was issued, except patients treated at 
the same time as they were diagnosed that we used as first 
date of diagnosis the suspected diagnosis date. The following 
laboratory and pathological factors were also recorded: 
tumour location (rectum or colon), degree of histological 
differentiation, tumour stage T and lymph node N (determined 
by the TNM clinical staging system), lymphovascular and 
perineural invasion, presence of metastasis, status of tumour 
markers such as carbohydrate antigen (CA) 19-9 and serial 
carcino-embryonic antigen (CEA). [37]
The following variables were self-reported by the 
patient: family history of colorectal cancer and other 
tumors, marital status, occupation at the time of the study, 
education profile, smoking habit and symptoms prior to 
surgery, date of onset of symptoms.
Statistical design
A descriptive analysis was performed, with measures 
of central tendency and dispersion for the quantitative 
variables and frequency distributions for the qualitative 
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ones. Differences were determined by bivariate analysis, 
segmenting by type of tumour and by time elapsed to first 
treatment, using the Student t test for quantitative variables 
and the chi-square test for qualitative ones. Finally, the 
treatment delay variable was used to perform a multivariate 
logistic regression analysis, using the variables with a value 
of p<0.1, together with the patient’s age and sex. The level 
of statistical significance used in these analyses was p<0.05.
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